ArticleBMC pulmonary medicine2026
Surgical strategy and prognostic factors in very elderly (≥ 75 Years) patients with stage I NSCLC: insights from a propensity score-matched analysis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal surgical strategy for very elderly patients (≥ 75 years) with stage I non–small cell lung cancer (NSCLC) remains uncertain.
methodsWe retrospectively analyzed 390 patients with pathologic stage I NSCLC (≤ 4 cm, N0) who underwent curative resection at two university-affiliated hospitals. Fifty-one patients were aged ≥ 75 years and 339 were < 75 years. Recurrence-free survival (RFS) was the primary endpoint, and overall survival (OS) was secondary. Propensity-score matching (PSM) balanced baseline factors, and multivariable Cox regression identified independent predictors of recurrence.
resultsOlder patients had significantly worse outcomes than younger ones (5-year RFS 65% vs. 82%, p < 0.001; OS 69% vs. 92%, p < 0.001). After PSM, age ≥ 75 remained an independent predictor of recurrence (HR 2.40, p = 0.015) and overall survival (HR 4.40, p < 0.001). In the very elderly subgroup, lobectomy provided superior recurrence control compared with sublobar resection (5-year RFS 76.6% vs. 50.8%; HR 3.57, p = 0.046). Tumor size > 2 cm also predicted poorer RFS (HR 3.41, p = 0.026). High-risk pathological features (poor differentiation, lymphovascular invasion (LVI), spread through air spaces (STAS) were predictive in the overall cohort but less so in the very elderly. Adjuvant chemotherapy had no significant effect on RFS.
conclusionsIn very elderly patients with stage I NSCLC, tumor size and surgical extent were the main predictors of recurrence. Lobectomy achieved superior recurrence-free survival, underscoring the importance of optimal oncologic clearance during initial surgery when adjuvant therapy is rarely feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.